New combo therapy aims to tame stubborn blood disorders
NCT ID NCT07574073
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This early-stage study tests whether combining two drugs (a CD20 antibody and a BTK inhibitor) can help people with refractory immune-related cytopenia—conditions where the immune system attacks blood cells, causing low platelets (ITP) or anemia (AIHA). About 30 adults aged 18-80 will receive the combination to see if it improves blood counts and how safe it is. The goal is to control the disease, not cure it, as ongoing management may still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BTK INHIBITORS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.